Fresh from the biotech pipeline: fewer approvals, but biologics gain share
Melanie Senior(Unknown)
Cited by 64
Related Papers
Novartis signs up for Google smart lens
|Nature Biotechnology|2014|152
After Glybera's withdrawal, what's next for gene therapy?
|Nature Biotechnology|2017|114
Checkpoint inhibitors go viral
|Nature Biotechnology|2019|39
Cancer-targeting antibody–drug conjugates drive dealmaking frenzy
|Nature Biotechnology|2024|28
Fresh from the biotech pipeline: record-breaking FDA approvals
|Nature Biotechnology|2024|25